

# The subscription price for exercise of warrants of series T05 in Lumito AB is set to SEK 0.75 and the subscription period commences today May 27

Lumito AB (publ) ("Lumito" or the "Company") issued warrants of series T05 in connection to an issue and loan financing during the fourth quarter of 2023. Each warrant gives the right to subscribe for one (1) new share in the Company. The subscription price for the warrants has been set to 70 percent of the volume-weighted average price of the Company's share on NGM Nordic SME during the measurement period, which runs from and including May 13, 2024, to and including May 24, 2024, however not less than the quota value for the Company's shares and not more than SEK 1.20. The volume-weighted average price of the Company's share during the measurement period amounted to approximately SEK 1.08 and thus the subscription price has been set at SEK 0.75. The subscription period for the warrants runs during the period from and including May 27, 2024, to and including June 10, 2024.

Complete terms for the warrants are available on the Company's website, [www.lumito.se/en/](http://www.lumito.se/en/).

**Summarised terms for the warrants of series T05:**

**Exercise period:** May 27, 2024 – June 10, 2024.

**Subscription price:** SEK 0.75 per share.

**Issue volume:** 34,406,248 warrants of series T05 entitles to subscription of 34,406,248 shares. If all warrants are exercised the Company will receive approximately SEK 25.8 million before issuing costs.

**Last day for trading with warrants:** June 4, 2024.

**Share capital and dilution:** If all warrants of series T05 are exercised the number of shares will increase with 34,406,248 shares from 206,437,488 shares to 240,843,736 shares and the share capital will increase with SEK 860,156.20, from SEK 5,160,937.20 to SEK 6,021,093.40, corresponding to a maximal dilution effect of 14.3 percent if the number of shares.

Note that the warrants that are not exercised at the latest June 10, 2024, or sold at the latest June 4, 2024, will expire without value. For the warrants of series T05 not to lose their value, the holder must actively subscribe for new shares or sell the warrants. Please note that some nominees may close registration earlier than June 10, 2024.

**How the warrants are exercised:****Nominee-registered warrants (custody account)**

Subscription and payment by exercise of warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information.

**Direct-registered warrants (securities account)**

No accounts for issuing nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form. The warrants will then be replaced by interim shares awaiting registration at the Swedish Companies Registration Office.

Application form and instructions for subscription are available on the Company's webpage, [www.lumito.se](http://www.lumito.se).

**Advisers**

Mangold Fondkommission AB is financial adviser and Advokatfirman Lindahl KB is legal advisor to Lumito in connection with the exercise of the warrants of series T05.

**For further information, please contact:**

---

Mattias Lundin, CEO Lumito  
E-mail: [ml@lumito.se](mailto:ml@lumito.se)  
Ph: +46 76 868 45 09

**Lumito**

---

**Lumito** specialises in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalised healthcare. The technology enables higher-contrast images without irrelevant background information, making it easier for pathologists to find cancer indications. The technology, based on Up Converting NanoParticles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shortened analysis times. The method has several potential applications, but Lumito has focused primarily on digital pathology and first on a release of SCIZYS by Lumito for use in research laboratories. The company is a spin-off of a research group at the Department of Atomic Physics and Laser Centre. [www.lumito.se/en](http://www.lumito.se/en)

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

**Attachments**

[The subscription price for exercise of warrants of series T05 in Lumito AB is set to SEK 0.75 and the subscription period commences today May 27](#)